Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2008-07-22
2008-07-22
Bertoglio, Valarie (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S014000, C800S018000
Reexamination Certificate
active
11093555
ABSTRACT:
This document provides materials and methods related to PAPP-A polypeptides, aging, and transgenic non-human mammals whose genomes comprise a disrupted PAPP-A allele. Methods for making such transgenic non-human mammals, and using them and other mammals to identify and characterize agents that affect conditions related to PAPP-A activity, such as vascular restenosis, atherosclerosis, wound healing, cancer, fibrosis, bone development, fetal development, longevity, and fracture repair, also are provided.
REFERENCES:
patent: 5849991 (1998-12-01), D'Apice et al.
patent: 6177610 (2001-01-01), Lee et al.
patent: 2002/0102252 (2002-08-01), Gu et al.
Harrison, SJ et al, 2002, Efficient generation of alpha(1,3) galactosyltransferase knockout porcine fetal fibroblasts for nuclear transfer, Transgenic Research, 11:143-150, 2002.
Thomson AJ et al., 2003, Gene targeting in livestock, Reprod. Supp., 61:495-508.
Wang, B et al. 2003, Specific genetic modifications of domezstic animal by gene targeting and animal cloning, Reproductive biology and endocrinology, 1 :103.
Wolfer, DP et al, 2002, Knockout mice: simple solutions to the problems of genetic background and flanking genes, Trends in Neurosciences, 25:336-340.
Holzenberger M. et al., 2004, IGF-1 signaling and aging, Experimental Gerontology, 39:1761-1764.
Moreadith, 1997, Gene targeting in embryonic stem cells : the new physiology and metabolism, Journal of Molecular Medicine, vol. 75, pp. 208-216.
Mullins, 1996, J. Clin. Invest., vol. 98, pp. S37-S40.
Coschigano, K et al., 2003, Endocrinology, 144:3799-3810.
Branch, A., 1998, A good antisense is hard to find, TIBS, 23:45-50.
Soe, R et al, 2002, FEBS, 269:2247-2256.
Agrawal S et al., 2000, Antisense therapeutics, is it as simple as complementary base recognition?, Molec Med Today, 6:72-81.
GenBank Accession No. AF258461 dated Sep. 2, 2000.
GenBank Accession No. X68280 dated Dec. 16, 1993.
Adams et al., “Developmental patterns of insulin-like growth factor-I and -II synthesis and regulation in rat fibroblasts,”Nature, 1983, 302:150-153.
Baker et al., “Role of Insulin-like Growth Factors in Embryonic and Postnatal Growth,”Cell, 1993, 75:73-82.
Boldt et al., “Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin,”Biochem. J., 2001, 358:359-367.
Breslow, “Mouse Models of Atherosclerosis,”Science, 1996, 272:685-688.
Burns and Hassan, “Cell survival and proliferation are modified by insulin-like growth factor 2 between days 9 and 10 of mouse gestation,”Development, 2001, 128:3819-3830.
Cibelli et al., “Cloned Transgenic Calves Produced from Nonquiescent Fetal Fibroblasts,”Science, 1998, 280:1256-1258.
Clemmons, “Insulin-like Growth Factor Binding Proteins and their Role in Controlling IGF Actions,”Cytokine Growth Factor Rev., 1977, 8(1):45-62.
Conover et al., “Cleavage Analysis of Insulin-like Growth Factor (IGF)-dependent IGF-binding Protein-4 Proteolysis and Expression of Protease-resistant IGF-binding Protein-4 Mutants,”J. Biol. Chem., 1995, 270(9):4395-4400.
DeChiara et al., “A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting,”Nature, 1990, 345:78-80.
Fowlkes, “Insulin-like Growth Factor-Binding Protein Proteolysis. An Emerging Paradigm in Insulin-like Growth Factor Physiology,”Trends Endocrinol. Metab., 1997, 8(8):299-306.
Holzenberger et al., “IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice,”Nature, 2003, 421:182-187.
Lawrence et al., “The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A,”Proc. Natl. Acad. Sci. USA, 1999, 96:3149-3153.
Liu et al., “Mice Carrying Null Mutations of the Genes Encoding Insulin-like Growth Factor 1 (Igf-1) and Type 1 IGF Receptor (Igf1r),”Cell, 1993, 75:59-72.
Ludwig et al., “Mouse Mutants Lacking the Type 2 IGF Receptor (IGF2R) Are Rescued from Perinatal Lethality inIgf2andIgf1rNull Backgrounds,”Dev. Biol., 1996, 177(2):517-535.
Nakashima et al., “ApoE-Deficient Mice Develop Lesions of All Phases of Atherosclerosis Throughout the Arterial Tree,”Arterioscler. Thromb., 1994, 14(1):133-140.
Orban et al., “Tissue- and site-specific DNA recombination in transgenic mice,”Proc. Natl. Acad. Sci. USA, 1992, 89(15):6861-6865.
Overgaard et al., “Expression of Recombinant Human Pregnancy-associated Plasma Protein-A and Identification of the Proform of Eosinophil Major Basic Protein as Its Physiological Inhibitor,”J. Biol. Chem., 2000, 275(40):31128-31133.
Plump et al., “Severe Hypercholesterolemia and Atherosclerosis in Apolipoprotein E-Deficient Mice Created by Homologous Recombination in ES Cells,”Cell, 1992, 71(2):343-353.
Qin et al., “Evidence That the Interaction between Insulin-like Growth Factor (IGF)-II and IGF Binding Protein (IGFBP)-4 Is Essential for the Action of the IGF-II-Dependent IGFBP-4 Protease,”Arch. Biochem. Biophys., 2000, 379(2):209-216.
Shastry, “Gene disruption in mice: Models of development and disease,”Mol. Cell. Biochem., 1998, 181:163-179.
Smith et al., “Development: Early-pregnancy origins of low birth weight,”Nature, 2002, 417:196.
Stewart and Rotwein, “Growth, Differentiation, and Survival: Multiple Physiological Functions for Insulin-Like Growth Factors,”Physiol. Rev., 1996, 76(4):1005-1026.
Vallette et al., “Construction of mutant and Chimeric genes using the polymerase chain reaction,”Nucl. Acids Res., 1989, 17(2):723-733.
Wakayama et al., “Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei,”Nature, 1998, 394(6691):369-374.
Wilmut et al., “Viable offspring derived from fetal and adult mammalian cells,”Nature, 1997, 385(6619):810-813.
Zaina et al., “Insulin-like Growth Factor II Plays a Central Role in Atherosclerosis in a Mouse Model,”J. Biol. Chem., 2002, 277(6):4505-4511.
Zhang et al., “Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E,”Science, 1992, 258:468-471.
Mazerbourg, S., et al., Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ovine, Bovine, Porcine, and Equine Ovarian Follicles: Involvement in IGF Binding Protein-4 Proteolytic Degraation and MRNA Expression During Follicular Development,Endocrinology, 142(12):5243-5253, 2001.
Griffiths et al., “Current Concepts of PLP and Its Role in the Nervous System,”Microscopy Research and Technique, 1998, 41:344-348.
Leonard et al., “Role of the Common Cytokine Receptor γ Chain in Cytokine Signaling and Lymphoid Development,”Immunol. Rev., 1995, 148:97-114.
Bertoglio Valarie
Fish & Richardson P.C.
Mayo Foundation for Medical Education and Research
LandOfFree
Longevity and PAPP-A does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Longevity and PAPP-A, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Longevity and PAPP-A will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3943648